The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Triggering global regulatory submissions this year for the treatment of obesity
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Subscribe To Our Newsletter & Stay Updated
